Med-Fine FamilyFinancing Progress
1.YUN HO BIOSecured Series A FinancingAugust 6, 2025 – YUN HO BIO recently announced the completion of its Series A financing round, with investment from Everfront Venture Capital. The amount of investment was not disclosed. YUN HO BIO is mainly engaged in AI-assisted extrahepatic siRNA drug research and development, medical research, experimental development, and biopharmaceutical R&D. The funds from this round of financing will be used to accelerate YUN HO BIO's R&D progress in the field of AI-assisted extrahepatic siRNA drug development.Learn MoreMed-Fine FamilyResearch Progress
1.Dan Qing PharmaceuticalsFirst Patient Enrolled in DAT-1604 Phase I Clinical TrialOn August 25, 2025, Danqing Pharmaceuticals announced the successful dosing of the first patient in the clinical study of its self-developed DNA polymerase theta (POLQ) inhibitor, DAT-1604.Learn More2.SHU MU JI HENGA Multi-Project Composite Prenatal Screening Quality Control Product and Its Preparation Method Patent ApprovedRecently, the invention patent "A Multi-Project Composite Prenatal Screening Quality Control Product and Its Preparation Method" applied for by Beijing Shuimu Jiheng Biotechnology Co., Ltd. has been authorized by the China National Intellectual Property Administration and has obtained the invention patent certificate. This invention patent provides a multi-project composite prenatal screening quality control product and its preparation method.Learn More03
Med-Fine FamilyBusiness Breakthrough
1.The Second Affiliated Hospital of Zhejiang University School of Medicine was among the first in China to launchAikema MedicalPFA Surgical Tour Successfully ConcludedRecently, as one of the first clinical application units in China, the Boao Medical District of the Second Affiliated Hospital of Zhejiang University School of Medicine successfully performed cardiac pulsed field ablation (PFA) surgeries on two atrial fibrillation patients using AccuPulse® disposable cardiac pulsed field ablation catheter and AccuBlator® cardiac pulsed field ablation system developed by Aicopulse Medical.The successful completion of the two surgeries not only marks the official entry of this innovative domestically-produced PFA system into the clinical application stage, but also, with its three core advantages of integrated circular catheter mapping and modeling, efficient ablation, and excellent safety, provides a better option for atrial fibrillation interventional treatment.Learn More2. Ensheng MedicalDebut of V-Mixtent® Stent at Liaoxi Vascular ForumThe 8th Western Liaoning Vascular Surgery Academic Exchange Conference successfully concluded on August 2, 2025. In the highly anticipated exhibition area of the conference, the EnSheng Medical booth attracted significant professional attention and in-depth discussions with its innovative product, the V-Mixtent® stent. At the exhibition site, a hands-on operational model of the product sparked great interest, particularly showcasing the compressive strength and bending tests of the V-Mixtent® sample stent. The core value of the V-Mixtent® stent lies in its unique modular design concept. The product features a groundbreaking "integrated carving and weaving structure," which strikes a golden balance between rigid support and flexible compliance. By enabling single-implant coverage of longer lesion areas, the V-Mixtent® stent significantly streamlines surgical procedures while offering patients a more convenient and efficient experience.。Learn More
3.Ningbo Municipal People's Congress Research Group VisitsSANOVABeijing Headquarters: A Joint Discussion on Technological Innovation and ResponsibilityRecently, the 2025 Training Program for Local People's Congress Deputies and Officials was held at the Conference Center of the National People's Congress. During the break of the learning activities, Zhang Jinjie, Vice President of Sanovas and a deputy of the Ningbo Municipal People's Congress, specially invited the trainees to visit the Beijing headquarters of Sanovas. Zhang Jindi, Chairman and President of Sanovas, warmly received the guests and provided an in-depth introduction and exchange on topics such as enterprise development, technological innovation, and the performance of deputies' duties. People's Congress deputies from various industries in Ningbo gathered at Sanovas to gain a practical understanding of the company’s development achievements and jointly discuss the practice and future of new quality productivity in the field of medical technology.Learn More
4.Professor Zheng Shaoyi's team from Nanfang Hospital completes the first bedside ultrasound-guided case in ChinaXinQing MedicalMoyoAssist® Successfully Implanted and Bridged to Heart TransplantRecently, under the overall coordination of Professor Zheng Shaoyi, Director of the Department of Cardiovascular Surgery at Nanfang Hospital, Southern Medical University, a multidisciplinary team of experts successfully applied a domestically produced fully magnetically levitated extracorporeal ventricular assist device (MoyoAssist® Extra VAD® by XinQiao Medical) to bridge the patient to heart transplantation. This marks the first case in China where the Extra VAD® was implanted under bedside transesophageal echocardiography guidance, avoiding the risk of worsening ventricular fibrillation and unstable circulation caused by patient transfer. The MoyoAssist® Extra VAD®, with its fully magnetically levitated centrifugal pump design, can provide up to 30 days of circulatory support and effectively reduce the left ventricular load, ensuring effective hemodynamic support for such patients.Learn More
5. ZHUODAO MedicalArmGuider® Pro Kids, a pediatric upper limb rehabilitation training robot, successfully obtains medical device registration certification.On July 31, 2025, the upper limb rehabilitation training robot for children, "ArmGuider® Pro Kids Pediatric Upper Limb Rehabilitation Training System" by ZHUODAO Medical®, successfully obtained the Class II Medical Device Registration Certificate of the People's Republic of China, with the registration certificate number: Hu Med Reg No. 20252190314, after being approved by the Shanghai Municipal Medical Products Administration.Learn More6.Jiajian MedicineFull Marks Achieved in Two NCCL External Quality Assessment Programs for 2025Recently, the National Center for Clinical Laboratories (NCCL) of the National Health Commission of China officially released the evaluation results of the "2025 Newborn Deafness Gene Detection (NDGM) External Quality Assessment" and the "2025 DMD Gene Detection External Quality Assessment." In this external quality assessment, Jiagen Medical achieved full marks with all testing samples meeting the expected standards, thanks to its solid technical expertise and rigorous quality management system. This outstanding performance fully demonstrates the laboratory's professional capabilities in genetic testing and the reliability of its high-quality testing services.Learn More7.MicroMedicineDebuting at NGDx2025: Intelligent Solutions to Tackle Localization ChallengesOn August 14-15, 2025, the NGDx2025 10th China Advanced Diagnostics Development and Application Forum was successfully held in Hangzhou. The conference focused on the application of IVD diagnostic technologies in the fields of infectious diseases and pathogenic microorganisms, early cancer screening/companion diagnostics/prognosis and recurrence monitoring, Alzheimer's disease (AD), and more. As a leading company in the field of precision diagnosis of infections in China, Dr. Zheng Yafeng, CTO of Microbiology Medicine, was invited to attend the conference. In the Pathogen and Microbiology Special Session, he delivered a keynote speech titled "Local Automated Solutions for High-Throughput Sequencing of Pathogens," providing innovative ideas and practical solutions to address the challenges of localizing pathogen testing and improving the efficiency of clinical diagnosis and treatment of infectious diseases.Learn More
8.Smart Veterinary Dual-Core Drive,CAS GENERelease Micro-Zhice and Vetailims to Redefine the Boundaries of Detection Efficiency
During the 12th Chinese Veterinary Congress, Beijing Zhongke Gene Technology Co., Ltd. held the "Smart Veterinary Dual-Core Drive Launch Event" on August 23 at the Xi'an International Convention and Exhibition Center. Themed "Reconstructing the Efficiency Boundary of Veterinary Diagnostics," the event officially launched two core products, MicroSmart Test (vetaiseq) and vetailims, injecting new momentum for digital and intelligent transformation into the veterinary industry.Learn More
Med-Fine Family Business Cooperation
1.SHU MU JING CHUANGAssisting Pansheng Bio Collagen Dressing in Obtaining Class III Registration CertificateOn August 22, Shuimu Jingchuang assisted Jinan Pansheng Biotechnology Co., Ltd. in successfully obtaining the Class III medical device approval from the National Medical Products Administration (NMPA) for its self-developed "Collagen Dressing."Learn More2. YipinAssisting DeMe Medical's BioCore™ Absorbable Interface Screw Approved for Marketing
In the wave of continuous innovation in medical technology, a significant breakthrough has recently been achieved — the official approval and market launch of BioCore™ Absorbable Interface Screws (Registration Certificate No.: 20253131601). This innovative product, which embodies cutting-edge technology and clinical practice wisdom, will inject new vitality into the field of orthopedic medicine and offer more valuable options for clinical treatment. The successful approval and market launch of BioCore™ Absorbable Interface Screws by DeMe Medical was supported throughout the entire process — from initial performance refinement during the research and development phase to compliance verification before market entry — by Yipin Laboratory’s comprehensive "in vitro - in vivo" experimental support. This effectively accelerated the translation process of BioCore™ Absorbable Interface Screws and provided scientific and rigorous technical support for its smooth approval and compliant market entry, helping this innovative product serve clinical needs more quickly.Learn More
Med-Fine FamilyIndustry Honors
1. Pengli Bio Ranks Among "Top 20 Preclinical CROs in China 2025"
2. SaiFu Pharma Ranks Among "Top 20 Preclinical CROs in China 2025"
3. Saffron Pharmaceuticals Honored in the 2025 China Healthcare Growth List – Top 100 in Medical and Health Industry Services
4. Ensheng Medical Awarded the 2025 Shanghai "Specialized, Precise, Unique, and Innovative" SME Certification
5. HeartPower Medical Nominated for 2025 Galien USA Awards Best Start-Up Award
6. Colubao Selected as a Technology-based SME Again
